NanoSyrinx strengthens senior R&D team
- Appointments of Dr Valentina Galli as Associate Research Director, Translational Biology, and Steve Ruscoe as Principal Scientist, Process Development
- Drug delivery and process development expertise further expands the Company’s R&D capabilities
Coventry, UK, 21st January 2025: NanoSyrinx, a synthetic biology company developing Nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, today announced the appointment of Dr Valentina Galli as Associate Research Director, Translational Biology, and Steve Ruscoe as Principal Scientist, Process Development. The appointments form part of the Company’s wider operational expansion to support the development of its Nanosyringe platform.
Dr Valentina Galli will lead the translational biology team at NanoSyrinx, developing and delivering in vitro and preclinical data for the validation of Nanosyringe candidates designed to address unmet patient needs. Valentina has over 10 years’ experience in the intracellular delivery of biologics, most recently at Evox Therapeutics as Associate Research Director, validating delivery technologies through in vivo proof of concept.
In addition, Steve Ruscoe joins the Company as Principal Scientist from Ipsen, bringing extensive experience in the development of sustainable and scalable microbial fermentation, including GMP compatible processes. While at Ipsen, Steve facilitated several successful regulatory submissions and approvals, driving the commercialisation of pharmaceutical products.
Valentina and Steve join NanoSyrinx alongside other new appointments, to expand the Company’s R&D capabilities, following the closure of its £10 million financing round in September 2024(1). These appointments will support all areas of platform development, bioprocess development, translational biology and operations as the Company focuses on further advancing its technology platform to accelerate the development of biologic therapeutics against previously ‘undruggable’ intracellular targets.
Dr. Joe Healey, Chief Executive Officer, NanoSyrinx said: “These appointments increase our specialist R&D capabilities and operational capacity as we continue advancing our unique Nanosyringe technology to address the challenges associated with intracellular delivery of therapeutics. We are focused on building a world-class team to drive this mission forward”
Dr. Valentina Galli, Associate Research Director, Translational Biology, NanoSyrinx added: “ Precise, targeted delivery is still a major barrier in the biologics field, and it needs creative and innovative solutions to ensure maximum therapeutic benefit with reduced adverse and off-target effects. NanoSyrinx’s unique approach to delivering intracellular therapeutics offers an innovative solution for addressing specific molecular targets inside the cell. I am excited to join the team and be a part of this work to open new avenues for treating diseases with a high unmet clinical need.”
